Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.
about
Elemental and chemically specific X-ray fluorescence imaging of biological systemsImpact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Intracellular distribution and stability of a luminescent rhenium(i) tricarbonyl tetrazolato complex using epifluorescence microscopy in conjunction with X-ray fluorescence imaging.Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging PropertiesA ruthenium(ii) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy.RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.Synchrotron-based X-ray-sensitive nanoprobes for cellular imaging.Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites for Organo-Osmium Complex in Human Ovarian Cancer Cells.X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae.Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol.A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells.A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A).NO Exchange for a Water Molecule Favorably Changes Iontophoretic Release of Ruthenium Complexes to the Skin.Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands.Cytotoxic hydrogen bridged ruthenium quinaldamide complexes showing induced cancer cell death by apoptosis.
P2860
Q28655858-F6C9F50E-345A-44DA-B4C5-48BE9BEC08E2Q35621511-D84F1A57-E3D2-4714-B616-CED3069AE299Q36086603-F985F5F3-B825-4D14-9F2A-E607EC41BC51Q36287265-46891E1D-7DBE-424C-847E-060346B302B4Q38096196-E02AF7DB-0F27-4157-9354-0800F817DB06Q38727966-0969B396-9138-4C20-8A5D-FCE53B9E4E15Q38753875-C4B24434-B794-4357-A9F1-141769D8C8BAQ38788535-CE63E2FA-65FA-4F32-BC64-02DD155D1028Q38838114-D4800795-976C-4E98-AF34-230E249FCE90Q38930683-986D509E-725D-4B96-9B5F-2B3E17E835D0Q38979908-8B7F3DA0-2007-45E8-BA69-E1E78A0E8BF3Q39009619-99A21E88-CF0A-4039-8CCF-CE777B4366A3Q39067087-B6BC6D85-B653-4451-A69D-FFE76AF9AF64Q39110547-B4AB9181-C214-4C06-9197-9A03A01855CCQ40737623-734FE361-4125-4A44-96DD-D60A4ABC11E3Q40759010-F5CE3060-FAC3-4418-B212-1B120E96A37AQ43242098-5D630015-E650-4904-A39E-78741A5A613FQ43811304-D470DC1B-CC2C-439D-8667-C97E67E9CED9Q44384757-4642E096-E894-4046-B67E-470A1DF4F066Q45968243-82D11C67-0592-4CFD-84D1-F3B93AB5F328Q46750665-411C5F60-B140-4D5D-B05A-4B22AA4FB4EAQ49517494-03929B90-4ADA-41A5-8937-9F7B53FDA6ABQ50249891-86041A45-DBC4-4A37-A65A-45649CADAE34Q50863499-0212B0C7-CECD-4BBE-8596-2C6A5DC3D459Q52815276-F2C107E9-628B-45E6-B916-638E25856AA2
P2860
Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Distinct cellular fates for KP ...... cence imaging of single cells.
@en
Distinct cellular fates for KP ...... cence imaging of single cells.
@nl
type
label
Distinct cellular fates for KP ...... cence imaging of single cells.
@en
Distinct cellular fates for KP ...... cence imaging of single cells.
@nl
prefLabel
Distinct cellular fates for KP ...... cence imaging of single cells.
@en
Distinct cellular fates for KP ...... cence imaging of single cells.
@nl
P2093
P2860
P356
P1433
P1476
Distinct cellular fates for KP ...... cence imaging of single cells.
@en
P2093
Jade B Aitken
Leone Spiccia
Sumy Antony
P2860
P304
1051-6, 1007
P356
10.1039/C2MT20072D
P577
2012-08-20T00:00:00Z